The Influence of Caffeine Supplementation on Specific Performance and Training Activities

Supplementation Clinical Trial

Official title:

The Influence of Caffeine Supplementation on Discipline-Specific Performance and Training Activities in Combat Sports and Speed-Strength Disciplines

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03822663
• Other study ID #: ULS00007
• Status: Completed
• Phase: Phase 3
• Start date: May 15, 2017
• Est. completion date: December 20, 2023

Study information

• Verified date: April 2024
• Source: Poznan University of Physical Education
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to verify the effect of acute caffeine (CAF) and placebo (PLA) supplementation on physical capacity and discipline-specific exercise performance in athletes, in a randomised, double-blind, placebo-controlled crossover trial.

Description:

Caffeine (CAF) is often proposed as an ergogenic agent, especially during high-intensity efforts. CAF supplementation may reduce effort-induced multi-faceted symptoms of fatigue and can improve psychomotor functions (like agility or decision-making processes), which is required during the intermittent high-intensity efforts in combat sports and speed-strength disciplines. Moreover, it is suggested that CAF treatment is associated with increased glycolytic activity during simulated or real training/competition bouts, which results in performance and physical capacity improvement.

However, there are hardly any data on the individual CAF-induced and dose-dependent changes in physical capacity and discipline-specific performance in combat sports and speed-strength disciplines. Therefore, the study aims to examine the effect of acute, different-dose CAF ingestion on physical capacity and discipline-specific performance in combat sports and speed-strength athletes, in a randomized, double-blind, placebo-controlled crossover trial.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 26
• Est. completion date: December 20, 2023
• Est. primary completion date: March 1, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 40 Years

Eligibility

Inclusion Criteria:

• written consent to participate,

• a current medical clearance to practice sports,

• training experience: at least 2 years,

• minimum of 4 workout sessions (in the discipline covered by the study) a week.

Exclusion Criteria:

• current injury,

• any health-related contraindication,

• declared general feeling of being unwell,

• unwilling to follow the study protocol.

Related Conditions & MeSH terms

• Sports
• Supplementation

Intervention

Dietary Supplement:
• Caffeine supplementation
The experimental procedure for each athlete includes an acute CAF supplementation in a different-dose crossover regimen in order to assess whether the dose affects the actual physical capacity and discipline-specific exercise performance (doses: 3.0-, 6.0- and 9.0 mg/kg of body mass, respectively). CAF (pure pharmaceutical caffeine) will be administered in the dissolved form. On testing days, the supplements will be taken 70 min before physical and exercise capacity test session. Between the CAF and PLA or a PLA and CAF treatments, a minimum 7-day washout period will be introduced.
• Placebo treatment
The experimental procedure for each athlete will include PLA supplementation. Placebo will be administered in the dissolved form. On testing days, the PLA will be taken 70 min before physical and exercise capacity test session. Between the PLA and CAF or a CAF and PLA treatments, a minimum 7-day washout period will be introduced.

Locations

Country	Name	City	State
Poland	Department of Sports Dietetics, Poznan University of Physical Education	Poznan	Wielkopolska

Sponsors (2)

Lead Sponsor	Collaborator
Poznan University of Physical Education	Poznan University of Life Sciences

Country where clinical trial is conducted

Poland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Changes in white blood cells and hematological indices (red blood cells, RBC) count in capillary blood before and after caffeine supplementation and placebo treatment	Assessment of the leukocytes (neutrophils, monocytes, lymphocytes, neutrophils:lymphocytes ratio) and the hematological indices (red blood cells, RBC)(count/L) count in capillary blood before and after discipline-specific exercise tests carried out at baseline, and after CAF and PLA supplementation	Baseline and during 1 day of acute CAF and PLA supplementation
Other	Changes in hematological indices (hemoglobin concentration, HGB) in capillary blood before and after caffeine supplementation and placebo treatment	Assessment of the hematological indices (hemoglobin concentration, HGB) (mmol/L) in capillary blood before and after discipline-specific exercise tests carried out at baseline, and after CAF and PLA supplementation	Baseline and during 1 day of acute CAF and PLA supplementation
Other	Changes in hematological indices (hematocrit, HCT) in capillary blood before and after caffeine supplementation and placebo treatment	Assessment of the hematological indices (hematocrit, HCT) (L/L) in capillary blood before and after discipline-specific exercise tests carried out at baseline, and after CAF and PLA supplementation	Baseline and during 1 day of acute CAF and PLA supplementation
Other	Changes in hematological indices (mean corpuscular volume, MCV; mean platelet volume, MPV) in capillary blood before and after caffeine supplementation and placebo treatment	Assessment of the hematological indices (mean corpuscular volume, MCV; mean platelet volume, MPV) (fL) in capillary blood before and after discipline-specific exercise tests carried out at baseline, and after CAF and PLA supplementation	Baseline and during 1 day of acute CAF and PLA supplementation
Other	Changes in hematological indices (mean corpuscular hemoglobin mass, MCH) in capillary blood before and after caffeine supplementation and placebo treatment	Assessment of the hematological indices (mean corpuscular hemoglobin mass, MCH) (fmol) in capillary blood before and after discipline-specific exercise tests carried out at baseline, and after CAF and PLA supplementation	Baseline and during 1 day of acute CAF and PLA supplementation
Other	Changes in hematological indices (mean corpuscular hemoglobin concentration, MCHC) in capillary blood before and after caffeine supplementation and placebo treatment	Assessment of the hematological indices (mean corpuscular hemoglobin concentration, MCHC) (mmol/L) in capillary blood before and after discipline-specific exercise tests carried out at baseline, and after CAF and PLA supplementation	Baseline and during 1 day of acute CAF and PLA supplementation
Other	Changes in hematological indices (platelet count, PLT) in capillary blood before and after caffeine supplementation and placebo treatment	Assessment of the hematological indices (platelet count, PLT) (count x 109/L) in capillary blood before and after discipline-specific exercise tests carried out at baseline, and after CAF and PLA supplementation	Baseline and during 1 day of acute CAF and PLA supplementation
Other	Changes in hematological indices (platelet hematocrit, PCT) in capillary blood before and after caffeine supplementation and placebo treatment	Assessment of the hematological indices (platelet hematocrit, PCT) (cL/L) in capillary blood before and after discipline-specific exercise tests carried out at baseline, and after CAF and PLA supplementation	Baseline and during 1 day of acute CAF and PLA supplementation
Other	Changes in hematological indices (platelet distribution width, PDW; platelet large cell ratio, PLCR; red blood cells distribution width - coefficient of variation, RDW-C) in capillary blood before and after caffeine supplementation and placebo treatment	Assessment of the hematological indices (platelet distribution width, PDW; platelet large cell ratio, PLCR; red blood cells distribution width - coefficient of variation, RDW-C) (%) in in capillary blood before and after discipline-specific exercise tests carried out at baseline, and after CAF and PLA supplementation	Baseline and during 1 day of acute CAF and PLA supplementation
Other	Changes in hematological indices (red blood cells distribution width - standard deviation, RDW-S) in capillary blood before and after caffeine supplementation and placebo treatment	Assessment of the hematological indices (red blood cells distribution width - standard deviation, RDW-S) (fL) in capillary blood before and after discipline-specific exercise tests carried out at baseline, and after CAF and PLA supplementation	Baseline and during 1 day of acute CAF and PLA supplementation
Other	Changes in nutritional status indices (concentration of urea and magnesium) in capillary blood before and after caffeine supplementation and placebo treatment	Assessment of the nutritional status indices (concentration of urea and magnesium) (mmol/L) in capillary blood before and after discipline-specific exercise tests carried out at baseline, and after CAF and PLA supplementation	Baseline and during 1 day of acute CAF and PLA supplementation
Other	Changes in nutritional status indices (concentration of glucose, calcium and phosphorans) in capillary blood before and after caffeine supplementation and placebo treatment	Assessment of the nutritional status indices (concentration of glucose, calcium and phosphorans) (mg/dL) in capillary blood before and after discipline-specific exercise tests carried out at baseline, and after CAF and PLA supplementation	Baseline and during 1 day of acute CAF and PLA supplementation
Other	Changes in muscle damage markers (concentration of creatine) in capillary blood before and after caffeine supplementation and placebo treatment	Assessment of the muscle damage markers (concentration of creatine) (µmol/L) in capillary blood before and after discipline-specific exercise tests carried out at baseline, and after CAF and PLA supplementation	Baseline and during 1 day of acute CAF and PLA supplementation
Other	Changes in muscle damage markers (activity of alanine aminotransferase, aspartate aminotransferase, creatine kinase, lactate dehydrogenase)) in capillary blood before and after caffeine supplementation and placebo treatment	Assessment of the muscle damage markers (activity of alanine aminotransferase, aspartate aminotransferase, creatine kinase, lactate dehydrogenase) (U/L) in capillary blood before and after discipline-specific exercise tests carried out at baseline, and after CAF and PLA supplementation	Baseline and during 1 day of acute CAF and PLA supplementation
Primary	Changes in discipline-specific exercise capacity after caffeine supplementation and placebo treatment	Assessment of the discipline-specific exercise capacity tests carried out at baseline, and after CAF and PLA supplementation	Baseline and during 1 day of acute CAF and PLA supplementation
Primary	Changes in caffeine and paraxanthine concencentrations in serum and saliva before and after caffeine supplementation and placebo treatment	Assessment of the caffeine and paraxanthine concencentrations (µg/mL), and paraxanthine/caffeine ratio in serum and saliva before and after discipline-specific exercise tests carried out at baseline, and after CAF and PLA supplementation. Additionally CYP1A2 enzyme activity was assessed by the determination of the mean time-corrected PRX/CAF RATIO in saliva.	Baseline and during 1 day of acute CAF and PLA supplementation
Primary	Changes in reaction and motor time (Vienna Test System) after caffeine supplementation and placebo treatment	Assessment of the reaction and motor time (Vienna Test System) (ms) before and after discipline-specific exercise tests carried out at baseline, and after CAF and PLA supplementation	Baseline and during 1 day of acute CAF and PLA supplementation
Primary	Changes in postural stability indices (COP velocity, Vcop) (posturographic platform AccuGaitTM) (after caffeine supplementation and placebo treatment	Assessment of the postural stability indices (COP velocity, Vcop) (posturographic platform AccuGaitTM) (cm/s) before and after discipline-specific exercise tests carried out at baseline, and after CAF and PLA supplementation	Baseline and during 1 day of acute CAF and PLA supplementation
Primary	Changes in postural stability indices (area 95 percentile, Area95) (posturographic platform AccuGaitTM) after caffeine supplementation and placebo treatment	Assessment of the postural stability indices (area 95 percentile, Area95) (posturographic platform AccuGaitTM) (cm2) before and after discipline-specific exercise tests carried out at baseline, and after CAF and PLA supplementation	Baseline and during 1 day of acute CAF and PLA supplementation
Secondary	Changes in sports training / competition activities after discipline-specific exercise tests	Assessment of the sports training / competition activities after discipline-specific exercise tests carried out at baseline, and after CAF and PLA supplementation	Baseline and during 1 day of acute CAF and PLA supplementation
Secondary	Changes in rate of perceived exertion after discipline-specific exercise tests	Assessment of the Borg Rating of Perceived Exertion (RPE) scale after discipline-specific exercise tests carried out at baseline, and after CAF and PLA supplementation	Baseline and during 1 day of acute CAF and PLA supplementation
Secondary	Changes in heart rate during discipline-specific exercise tests	Assessment of the Heart Rate during and after discipline-specific exercise tests carried out at baseline, and after CAF and PLA supplementation	Baseline and during 1 day of acute CAF and PLA supplementation
Secondary	Analysis of psychological state before and after caffeine supplementation and placebo	Assessment of psychological state by chosen questionnaires was carried out before and after discipline-specific exercise tests carried out at baseline, and after CAF and PLA supplementation	Baseline and during 1 day of acute CAF and PLA supplementation
Secondary	Analysis of macronutrients in diets before and after caffeine supplementation and placebo treatment	Assessment of the macronutrients in diets (g) was carried out before the execution of exercise protocols on each research visit	Baseline and during 1 day of acute CAF and PLA supplementation
Secondary	Analysis of body composition (fat-free mass, fat mass)	Assessment of body composition (fat-free mass, fat mass) (kg) was carried out before the execution of exercise protocols on each research visit	Baseline and during 1 day of acute CAF and PLA supplementation
Secondary	Analysis of body composition (total body water)	Assessment of body composition (total body water) (%) was carried out before the execution of exercise protocols on each research visit	Baseline and during 1 day of acute CAF and PLA supplementation
Secondary	Changes in lactate and pyruvate concentrations in capillary blood before and after caffeine supplementation and placebo treatment	Assessment of the lactate and pyruvate concentration (mmol/L) in capillary blood before and after discipline-specific exercise tests carried out at baseline, and after CAF and PLA supplementation	Baseline and during 1 day of acute CAF and PLA supplementation
Secondary	Analysis of gene polymorphisms	Assessment of the chosen gene polymorphisms in saliva carried out at baseline	Baseline